NUCC-390 NEW
| Price | $117 | $289 | $455 |
| Package | 1mg | 5mg | 10mg |
| Supply Ability: | 10g |
| Update Time: | 2026-06-02 |
Product Details
| Product Name: NUCC-390 | CAS No.: 1060524-97-1 |
| Purity: 98.18% | Supply Ability: 10g |
| Release date: 2026/06/02 |
Product Introduction
Bioactivity
| Name | NUCC-390 |
| Description | NUCC-390, a novel small-molecule CXCR4 receptor agonist, selectively induces CXCR4 receptor internalization while acting antagonistically to AMD3100. This compound facilitates nerve functional recovery following neurodegeneration in vivo. |
| In vitro | NUCC-390 (10 μM) elicits a strong (Ca)i response, which can be blocked by the potent and selective CXCR4 antagonist AMD3100. Pre-treatment with NUCC-390 (10 μM; 30 mins) increases pERK levels, stimulating signaling activity downstream of CXCR4 receptors. NUCC-390 (10 μM; 2 hours) induces CXCR4 receptor internalization, while non-treated cells show diffuse CXCR4-YFP expression in the cytosol and clear membrane expression in HEK cells[1]. Additionally, NUCC-390 (0-1.25 μM; 24 hours) enhances axonal growth in cultured cerebellar granule neurons (CGNs) via CXCR4[2]. |
| In vivo | NUCC-390 (hind limb injection; 3.2 mg/kg; twice daily; 3 days) enhances functional and anatomical recovery of the neuromuscular junction (NMJ) after acute nerve terminal damage by α-LTx in CD-1 mice[2]. |
| Storage | Pure form: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 165 mg/mL (417.15 mM), Sonication is recommended. 10% DMSO+90% Saline : 10 mg/mL (25.28 mM), Suspension. |
| Keywords | NUCC-390 | NUCC390 | NUCC 390 | CXCR4 |
| Inhibitors Related | AZD8309 | rac-NBI-74330 | Tannic acid | Artemotil | CXCR2-IN-1 | Kynurenic acid | Soquelitinib | Plerixafor octahydrochloride | Tanimilast | 3-Indoleglyoxylic acid | Nicotinamide N-oxide | CXCL-CXCR1/2-IN-1 |
| Related Compound Libraries | Bioactive Compound Library | Cytokine Inhibitor Library | Membrane Protein-targeted Compound Library | Hematonosis Compound Library | Autophagy Compound Library | Chemokine Inhibitor Library | Angiogenesis related Compound Library | Immuno-Oncology Compound Library | Immunology/Inflammation Compound Library | Bioactive Compounds Library Max | GPCR Compound Library | Anti-Cancer Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
-
-
CAS:128496-10-6
-
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $1350.00 |
VIP2Y
|
TargetMol Chemicals Inc.
|
2026-07-15 | |
|
VIP3Y
|
Xian confluore Biological Technology Co., Ltd.
|
2025-06-07 | ||
| $117.00 |
VIP6Y
|
TargetMol Chemicals Inc.
|
2026-06-02 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, USA
INQUIRY